- Home
- XERS vs SDHY Comparison
XERS vs SDHY Comparison
Compare XERS & SDHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XERS
- SDHY
- Stock Information
- Founded
- XERS 2005
- SDHY 2020
- Country
- XERS United States
- SDHY United States
- Employees
- XERS N/A
- SDHY N/A
- Industry
- XERS Biotechnology: Pharmaceutical Preparations
- SDHY Finance/Investors Services
- Sector
- XERS Health Care
- SDHY Finance
- Exchange
- XERS Nasdaq
- SDHY Nasdaq
- Market Cap
- XERS 444.0M
- SDHY 396.5M
- IPO Year
- XERS 2018
- SDHY N/A
- Fundamental
- Price
- XERS $3.09
- SDHY $16.60
- Analyst Decision
- XERS Buy
- SDHY
- Analyst Count
- XERS 3
- SDHY 0
- Target Price
- XERS $4.87
- SDHY N/A
- AVG Volume (30 Days)
- XERS 1.9M
- SDHY 94.0K
- Earning Date
- XERS 11-08-2024
- SDHY 01-01-0001
- Dividend Yield
- XERS N/A
- SDHY 8.46%
- EPS Growth
- XERS N/A
- SDHY N/A
- EPS
- XERS N/A
- SDHY 1.07
- Revenue
- XERS $187,361,000.00
- SDHY N/A
- Revenue This Year
- XERS $20.35
- SDHY N/A
- Revenue Next Year
- XERS $16.14
- SDHY N/A
- P/E Ratio
- XERS N/A
- SDHY $14.31
- Revenue Growth
- XERS 22.72
- SDHY N/A
- 52 Week Low
- XERS $1.69
- SDHY $13.93
- 52 Week High
- XERS $3.64
- SDHY $15.50
- Technical
- Relative Strength Index (RSI)
- XERS 49.74
- SDHY 51.84
- Support Level
- XERS $2.82
- SDHY $16.39
- Resistance Level
- XERS $3.12
- SDHY $16.62
- Average True Range (ATR)
- XERS 0.18
- SDHY 0.15
- MACD
- XERS -0.03
- SDHY -0.01
- Stochastic Oscillator
- XERS 32.93
- SDHY 37.50
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.
About SDHY PGIM Short Duration High Yield Opportunities Fund
PGIM Short Duration High Yield Opportunities is a closed-end management investment company. The fund's investment objective is to provide total return, through a combination of current income and capital appreciation. Its seeks to achieve its objective by investing in a diversified portfolio of high yield fixed income instruments.